Forian (Forian) Risk Assessment

View and export this data going back to 2021. Start your Free Trial

What is Forian Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Forian is: No Data: Cannot be evaluated.

Competitive Comparison of Forian's Risk Assessment

For the Health Information Services subindustry, Forian's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Forian's Risk Assessment Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Forian's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Forian's Risk Assessment falls into.

Forian (NAS:FORA) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Forian Risk Assessment Related Terms

Thank you for viewing the detailed overview of Forian's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Forian (Forian) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Forian Inc (NAS:FORA) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

41 University Drive, Suite 400, Newtown, PA, USA, 18940

Website

https://www.forian.com

Forian Inc provides a suite of SaaS solutions, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer and provider segments, as well as cannabis dispensaries, manufacturers, cultivators, and regulators.

Executives

Martin J Wygod	director	P.O. BOX 676306, RANCHO SANTA FE CA 92067
Trotman Stanley S Jr	director
Max C Wygod	director, officer: Executive Chairman	41 UNIVERSITY PLACE, SUITE 400, NEWTOWN PA 18940
Max Wygod Family Dynasty Trust	10 percent owner	41 UNIVERSITY DRIVE, SUITE 400, NEWTOWN PA 18940
Michael Vesey	officer: Chief Financial Officer	4041-T HADLEY ROAD, S. PLAINFIELD NJ 07080
Jennifer Hajj	director	41 UNIVERSITY PLACE, SUITE 400, NEWTOWN PA 18940
Kristiina Md Vuori	director	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Scott Matthew Ogur	director	C/O HELIX TCS, INC., 10200 E. GIRARD AVENUE, SUITE B420, DENVER CO 80231
Farren Clifford A Jr	officer: Chief Financial Officer	C/O SYNAVANT INC, 3445 PEACHTREE ROAD NE SUITE 1400, ATLANTA GA 30326
Adler Mark J Md	director
Ian Banwell	director	P.O. BOX 34004, CHARLOTTE NC 28234
Shahir Kassam-adams	director	41 UNIVERSITY PLACE, SUITE 400, NEWTOWN PA 18940
Adam H Dublin	director, officer: Chief Strategy Officer	41 UNIVERSITY PLACE, SUITE 400, NEWTOWN PA 18940
Daniel J Barton	director, officer: Chief Executive Officer	41 UNIVERSITY PLACE, SUITE 400, NEWTOWN PA 18940
Alyssa F Varadhan	director	41 UNIVERSITY PLACE, SUITE 400, NEWTOWN PA 18940